Abstract

Breast cancer is the most often observed worldwide as the second cause of cancer-related death in women. High resistin level is associated with breast cancer, therefore it is considered as a breast cancer biomarker. For a real data set, the article shows that mean resistin is positively associated with monocyte chemoattractant protein-1 (MCP-1) (p<0.0001), types of patients (p<0.0001), interaction effect of Body Mass Index (BMI) and leptin (BMI*Leptin) (p=0.0415), Homeostasis Model Assessment Score (HOMA)*Age (p=0.1059), Adiponectin (p=0.1111), while it is negatively associated with HOMA (p=0.0698), Age (p=0.1249), Leptin*Adiponectin (p=0.0736), Glucose*Adiponectin (p=0.1007). Variance of resistin is positively associated with class of patients (p=0.0114) and BMI (p=0.0942). Some partially significant effects (around 15% level of significance) are included in the models treated as confounder according to Epidemiology. It is concluded that resistin is higher for younger women with breast cancer, higher levels of MCP-1, adiponectin, and higher interaction effects of BMI*Leptin, Age*HOMA.

Keywords: Adiponectin; BMI; Breast cancer; Leptin; MCP-1; Resistin; Non-constant variance